Resolution of Left Bundle Branch Block Due To Treatment of COVID-19-Related Myocarditis

Abstract

We present the case of a 67-year-old woman with novel coronavirus-infected pneumonia, who was subsequently diagnosed with coronavirus disease 2019 (COVID-19)-related myocarditis and left bundle branch block (LBBB). COVID-19-infected pneumonia treatment, such as oseltamivir, azithromycin, ceftriaxone, and ascorbic acid, may be related to the reduction of myocarditis lesion. Reduction in lesions’ size may improve the conduction system; therefore, LBBB can also be resolved in the treatment of COVID-19-infected pneumonia

Keywords

• Left bundle branch block
• COVID-19
• myocarditis

COVID-19 İlişkili Miyokardite Bağlı Geri Dönüşümlü Sol Dal Bloğu

Abstract

Burada, COVID-19 ilişkili miyokardit ve geri dönüşümlü sol dal bloğu tanısı konan, yeni koronavirüs infekte pnömonili 67 yaşında bir kadın hasta sunulmuştur. Oseltamivir, azitromisin, seftriakson ve askorbik asit dahil olmak üzere COVID-19 infekte pnömoni tedavisi miyokardit lezyonunun azalmasıyla ilişkili olabilir. COVID-19 infekte pnömonide tedavi ile lezyonların boyutunda gerileme iletim sisteminde, dolayısıyla sol dal bloğunda iyileşmeye neden olabilir. Burada, COVID-19 ilişkili miyokardit ve geri dönüşümlü sol dal bloğu tanısı konan, yeni koronavirüs infekte pnömonili 67 yaşında bir kadın hasta sunulmuştur. Oseltamivir, azitromisin, seftriakson ve askorbik asit dahil olmak üzere COVID-19 infekte pnömoni tedavisi miyokardit lezyonunun azalmasıyla ilişkili olabilir. COVID-19 infekte pnömonide tedavi ile lezyonların boyutunda gerileme iletim sisteminde, dolayısıyla sol dal bloğunda iyileşmeye neden olabilir.

Keywords

• Sol dal bloğu
• COVID-19
• miyokardit

References

1. 1. Silva AMOCD, Silva EAGLD. Intermittent left bundle branch blockreversal to normal conduction during general anesthesia. Rev Bras Anestesiol 2017;67:430-4.
2. 2. Denison MR, Graham RL, Donaldson EF, Eckerle LD, Baric RS. Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity. RNA Biol 2011;8:270-9.
3. 3. Cizgici AY, Zencirkiran Agus H, Yildiz M. COVID-19 myopericarditis: It should be kept in mind in today’s conditions. Am J Emerg Med 2020:S0735-6757(20)30310-7.
4. 4. Jia-Hui Z, Ying-Xia L, Jing Y, Fu-Xiang W, Wei-Bo W, Jin-Xiu L. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection 2020 Apr 10.
5. 5. Burch GE, Giles TD. The role of viruses in the production of heart disease. Am J Cardiol 1972;29:231-40.
6. 6. Nakashima H, Honda Y, Katayama T. Serial electrocardiographic findings in acute myocarditis. Intern Med 1994;33:659-66.
7. 7. Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary pathology of early-phase 2019 Novel Coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol 2020;15:700-4.
8. 8. Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 2020 Mar 14;34.

9. 9. Ellulu MS, Rahmat A, Patimah I, Khaza’ai H, Abed Y. Effect of vitamin C on inflammation and metabolic markers in hypertensive and/or diabetic obese adult: a randomized controlled trial. Drug Des Devel Ther 2015;9:3405-12. 10. Jones SR, Herskowitz A, Hutchins GM, Baughman KL. Effects of immunosuppressive therapy in biopsy-proved myocarditis and borderline myocarditis on left ventricular function. Am J Cardiol 1991;68:370-6.